2022
Differences in Quantification of the Metabotropic Glutamate Receptor 5 Across Bipolar Disorder and Major Depressive Disorder
Holmes S, Asch R, Davis M, DellaGioia N, Pashankar N, Gallezot J, Nabulsi N, Matuskey D, Sanacora G, Carson R, Blumberg H, Esterlis I. Differences in Quantification of the Metabotropic Glutamate Receptor 5 Across Bipolar Disorder and Major Depressive Disorder. Biological Psychiatry 2022, 93: 1099-1107. PMID: 36764853, PMCID: PMC10164841, DOI: 10.1016/j.biopsych.2022.10.018.Peer-Reviewed Original ResearchConceptsMajor depressive disorderMetabotropic glutamate receptor 5Glutamate receptor 5MGluR5 availabilityBipolar disorderPositron emission tomographyHC groupDepressive disorderReceptor 5Emission tomographyHealthy control individualsPossible treatment targetsGlutamate transmissionBD depressionTreatment strategiesBD groupMGluR5Depressive symptomsNovel treatmentsCognitive alterationsTreatment targetsSynaptic plasticityControl individualsAccurate diagnosisSignificant negative correlation
2016
Ketamine’s Mechanisms of Rapid Antidepressant Activity: Evidence from Preclinical Studies
Hermes G, Sanacora G. Ketamine’s Mechanisms of Rapid Antidepressant Activity: Evidence from Preclinical Studies. 2016, 73-98. DOI: 10.1007/978-3-319-42925-0_6.Peer-Reviewed Original ResearchAntidepressant activityPreclinical studiesAntidepressant actionKetamine's mechanismPreclinical literatureRodent modelsRapid onsetBrain-derived neurotrophic factor (BDNF) expressionBehavioral effectsClassic antidepressant drugsRapid antidepressant activityNeurotrophic factor expressionChronic stressor exposureReceptor-targeted drugsNovel drug developmentAntidepressant propertiesKetamine effectsClinical trialsAntidepressant drugsSynaptic plasticityReceptor activationClinical settingFactor expressionStressor exposureDurable effects